New strategies in breast cancer: Immunotherapy

Lajos Pusztai, Thomas Karn, Anton Safonov, Maysa M. Abu-Khalaf, Giampaolo Bianchini

Research output: Contribution to journalArticlepeer-review

Abstract

More than 70% of breast cancers contain lymphocytic infiltration in the stroma, and preclinical studies suggest that immunoediting and partial control of cancer progression by the local immune microenvironment operate in most breast cancers. Consistent with this hypothesis, a large number of studies demonstrated a favorable prognostic and chemotherapy response predictive role for immune infiltration in breast cancer. The evidence is particularly strong for triple-negative and HER2-positive cancers. The development of clinically effective immune checkpoint inhibitors now provides an opportunity to test the therapeutic potential of augmenting the local antitumor immune response. Several phase I clinical trials using single-agent anti-PD-1 and anti-PD-L1 antibodies demonstrated objective tumor response rates, with remarkably durable responses, in heavily pretreated, metastatic, triplenegative cancers and somewhat lower responses in estrogen receptor-positive cancers. Currently, close to 50 ongoing, or soon to open, clinical trials evaluate the role of this new treatment modality in breast cancer.

Original languageEnglish
Pages (from-to)2105-2110
Number of pages6
JournalClinical Cancer Research
Volume22
Issue number9
DOIs
Publication statusPublished - May 1 2016

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'New strategies in breast cancer: Immunotherapy'. Together they form a unique fingerprint.

Cite this